Addex Therapeutics has led a CHF 2 million investment in Stalicla to advance precision medicine for neurodevelopmental disorders, particularly autism.

Information on the Target

Stalicla SA is a Swiss clinical-stage biopharmaceutical company dedicated to advancing precision medicine for neurodevelopmental and neuropsychiatric disorders. With over $50 million raised in equity and an additional $30 million in non-dilutive funding, Stalicla has developed a clinically validated neuro-precision development platform that identifies stratified patient subgroups. This strategic focus allows for the advancement of personalized treatment options tailored to the needs of this patient population.

Currently, Stalicla is preparing to initiate Phase 2 clinical trials for its leading drug candidate, STP1, and a second asset, both of which target specific subpopulations within the autism spectrum disorder (ASD). Additionally, its program STP7, which involves the drug mavoglurant, is moving towards Phase 3 trials, thanks to full funding provided by the U.S. government.

Industry Overview in Switzerland

The biopharmaceutical industry in Switzerland is robust and characterized by significant investment in research and development. Switzerland is home to a high concentration of pharmaceutical companies that are at the forefront of innovation, particul